---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000091"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:49:26.766062+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions closes sale of travel health business to Bavarian Nordic for $270M upfront

## Summary
- Emergent closed sale of travel health business to Bavarian Nordic on May 15, 2023 for $270M upfront cash.
- Potential milestone payments: up to $80M for CHIKV VLP development/approval and $30M earnout on 2026 net sales.
- Assets sold include typhoid vaccine Vivotif, cholera vaccine Vaxchora, CHIKV VLP candidate, Bern manufacturing site, San Diego development facilities.
- Majority of employees supporting these products and facilities are joining Bavarian Nordic.

## SEC filing metadata
- accession: 0001367644-23-000091
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/0001367644-23-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/ebs-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000091
- JSON: https://secwatch.observer/filing/0001367644-23-000091.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000091.txt

## Key facts
- M&A Transactions
  Emergent BioSolutions Inc. completed a disposition involving Bavarian Nordic for $270 million (closed 2023-05-15).
  - Action: disposition
  - Counterparty: Bavarian Nordic
  - Consideration: $270 million
  - Closing: 2023-05-15
  source text: the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. At the closing, Buyer paid a cash purchase price of $270 million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing (the "Purchase Price"). Bavarian Nordic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/0001367644-23-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.